Abstracts - faqs.org

Abstracts

Health

Search abstracts:
Abstracts » Health

Treatments for wasting in patients with the acquired immunodeficiency syndrome

Article Abstract:

There are many treatments for the wasting syndrome that occurs in many AIDS patients. Wasting syndrome is diagnosed if the patient has lost more than 10% of body weight and also has diarrhea, weakness or fever. Nutritional supplements and appetite stimulants may be effective as can testosterone and other anabolic steroids. Growth hormone may be beneficial in high doses but the safety of long-term use is unknown. Exercise may be beneficial but the effects of regular exercise in people with wasting syndrome is unknown. The development of more effective AIDS drugs may reduce the risk of wasting syndrome.

Author: Corcoran, Colleen, Grinspoon, Steven
Publisher: Massachusetts Medical Society
Publication Name: The New England Journal of Medicine
Subject: Health
ISSN: 0028-4793
Year: 1999
Care and treatment, Wasting syndrome, AIDS (Disease)

User Contributions:

Comment about this article or add new information about this topic:

CAPTCHA


Metformin in the Treatment of HIV Lipodystrophy Syndrome: A Randomized Controlled Trial

Article Abstract:

The drug metformin may be effective in treating lipodystrophy syndrome in HIV patients. Lipodystrophy syndrome causes a redistribution of fat, including an increase in fat on the trunk and abdomen and a loss of fat on the face and extremities. Another sign of lipodystrophy is insulin resistance, which is considered a precursor of diabetes. In a study of 26 HIV patients with lipodystrophy syndrome, metformin improved insulin metabolism and reduced abdominal fat.

Author: Hadigan, Colleen, Corcoran, Colleen, Basgoz, Nesli, Davis, Benjamin, Sax, Paul, Grinspoon, Steven
Publisher: American Medical Association
Publication Name: JAMA, The Journal of the American Medical Association
Subject: Health
ISSN: 0098-7484
Year: 2000
Evaluation, Drug therapy, Metformin, Lipid metabolism disorders, Lipidosis

User Contributions:

Comment about this article or add new information about this topic:

CAPTCHA


Growth hormone-releasing hormone in HIV-infected men with lipodystrophy

Article Abstract:

The human immunodeficiency virus (HIV) lipodystrophy syndrome is rampant in patients receiving antiretroviral therapy and tests were conducted to study the effects of growth hormone-releasing hormone (GHRH) in treatment of this syndrome. GHRH was tolerated while increasing levels of IGF-1 in HIV -infected men with lipodystrophy.

Author: Grinspoon, Steven, Koutkia, Polyxeni, Canavan, Bridget, Breu, Jeff, Torriani, Martin, Kissko, John
Publisher: American Medical Association
Publication Name: JAMA, The Journal of the American Medical Association
Subject: Health
ISSN: 0098-7484
Year: 2004
United States, Science & research, Research, Usage, Influence, Somatotropin releasing hormone, Somatotropin-releasing hormone, Highly active antiretroviral therapy, Lipodystrophy

User Contributions:

Comment about this article or add new information about this topic:

CAPTCHA


Subjects list: Complications and side effects, HIV infection, HIV infections
Similar abstracts:
  • Abstracts: Hyponatremia in patients with acquired immune deficiency syndrome. HIV-associated autoimmune hemolytic anemia: report of a case and review of the literature
  • Abstracts: Pulmonary aspergillosis in the acquired immunodeficiency syndrome. A randomized trial of itraconazole in allergic bronchopulmonary aspergillosis
  • Abstracts: Shared risk factors for falls, incontinence, and functional dependence: unifying the approach to geriatric syndromes
  • Abstracts: Evaluation of a screening algorithm for the diagnosis of genital infections with Neisseria gonorrhoeae and Chlamydia trachomatis among female sex workers in Benin
  • Abstracts: International Conference Considers Health Needs of the Rural Elderly. Aging prisoners stressing health care system
This website is not affiliated with document authors or copyright owners. This page is provided for informational purposes only. Unintentional errors are possible.
Some parts © 2025 Advameg, Inc.